A Systematic review and meta-analysis of cohorts on enoxaparin dosing regimens in adult hospitalized patients

Heba Ramadan

doi:10.55940/medphar202479

Authors

Heba Ramadan Pharmacy Department, Agamy Medical District, Ministry of Health and Population, Alexandria

DOI:

https://doi.org/10.55940/medphar202479

Keywords:

enoxaparin, low-molecular-weight heparin, dosing, hospitalized patients

Abstract

Background Enoxaparin, a low-molecular-weight heparin, is widely used for hospitalized patients for prophylaxis and situations associated with ischemic complications due to its anticoagulant and anti-inflammatory effects. In this study, enoxaparin dosage regimens are demonstrated to show adherence to the standard dose in different conditions. Methods This was applied through searching in Scopus, WOS, and Pubmed. A PRISMA checklist was followed. Quality assessment was checked. Statistical and meta-analysis were conducted by SPSS, Version 28 and the R-4.3.2 package. Results Seventeen retrospective cohort studies were included in the final analysis. Eight studies concerned COVID-19 patients. The total number of patients in the non-COVID-19 group studies is 28233; 15421 (49%, 0.4-0.59 95% C.I.) of them received a standard dose. The total number of patients in the COVID-19 group studies is 54099; no patients received a reduced dose; and 38006 (60%, 0.45-0.74 95% C.I.) received a standard dose. For non-COVID 19 studies, there is a significant difference in the means of patient number percentage received standard dose or reduced dose and those received overdose (Sig.<0.05, C.I. 95%) in favor of the standard dose or reduced dose and no significant difference in the means of patient number percentage received standard dose and those received reduced dose (Sig. = 0.56, C.I. =95%). For COVID-19 studies, there is no significant difference in the means of patient number percentage received standard dose and those received overdose (Sig. =0.094 , C.I. =95%). Conclusion Using definite tools to determine the most safe and effective enoxaparin dosage regimens is required.

References

Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Netw Open. 2023; 6(12): e2345883. doi:10.1001/jamanetworkopen.2023.45883

Segon YS, Summey RD, Slawski B, Kaatz S. Surgical venous thromboembolism prophylaxis: clinical practice update. Hosp Pract (1995). 2020; 48(5): 248-57. doi:10.1080/21548331.2020.1788893

Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2020; 42(14): 1289-367. doi:10.1093/eurheartj/ehaa575

van Gameren M, Lemmert ME, Wilschut JM, Daemen J, De Jaegere PPT, Zijlstra F, et al. An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction. Expert Opinion on Pharmacotherapy. 2018; 19(13): 1441-50. doi:10.1080/14656566.2018.1512583

Anonymous. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy: Correction. Obstet Gynecol. 2018; 132(4): 1068. doi:10.1097/AOG.0000000000002923

Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances. 2022; 6(17): 4915-23. doi:10.1182/bloodadvances.2022007561

Shaikh SA, Regal RE. Dosing of Enoxaparin in Renal Impairment. P T. 2017; 42(4): 245-9.

Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008; 111(10): 4871-9. doi:10.1182/blood-2007-10-120543

Sebaaly J, Covert K. Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. Annals of Pharmacotherapy. 2018; 52(9): 898-909. doi:10.1177/1060028018768449

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. doi:10.1136/bmj.n71

Al‐Jader L, Newcombe R, Hayes S, Murray A, Layzell J, Harper P. Developing a quality scoring system for epidemiological surveys of genetic disorders. Clinical genetics. 2002; 62(3): 230-4.

Weerasaksanti A, Siwamogsatham S, Kunlamas Y, Bunditanukul K. Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome. Bmc Cardiovascular Disorders. 2023; 23(1). doi:10.1186/s12872-023-03278-9

Knox H, Edwin SB, Giuliano C, Paxton RA. Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients. Journal of Intensive Care Medicine. 2023. doi:10.1177/08850666231217693

Nemeth A, Isherwood M. Safety and Effectiveness of Reduced Dose Versus Standard Dose Enoxaparin Venous Thromboembolism Prophylaxis in Underweight Medically Ill Patients. Hospital Pharmacy. 2023; 58(2): 178-82. doi:10.1177/00185787221123220

Buckheit D, Lefemine A, Sobieraj DM, Hobbs L. Venous Thromboembolism Prophylaxis in Underweight Hospitalized Patients. Clinical and Applied Thrombosis/Hemostasis. 2021; 27. doi:10.1177/10760296211018752

Lee YR, Palmere PJ, Burton CE, Benavides TM. Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study. Clinical Drug Investigation. 2020; 40(1): 33-40. doi:10.1007/s40261-019-00855-9

Seo B, Yang Y-M, Choi EJ. A retrospective study of enoxaparin dosing in cancer patients based on renal function in South Korea. Yakhak Hoeji. 2018; 62(2): 109-17.

Costantini TW, Min E, Box K, Tran V, Winfield RD, Fortlage D, et al. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. The journal of trauma and acute care surgery. 2013; 74(1): 128.

Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV, et al. Weight‐based dosing of enoxaparin in obese patients with non‐ST‐segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2009; 29(6): 631-8.

LaPointe NMA, Chen AY, Alexander KP, Roe MT, Pollack CV, Lytle BL, et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non–ST-segment elevation acute coronary syndromes. Archives of internal medicine. 2007; 167(14): 1539-44.

Chakabva MS, Polina S, Brauner M, McGuire M, Brown Z, Akthar T, et al. Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection. Hospital Pharmacy. 2023. DOI:10.1177/00185787231194997

Mora-Delgado J, Lojo-Cruz C, Marín PR, Campos EMM, Michán-Doña A. Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. Journal of Clinical Medicine. 2023; 12(3). DOI:10.3390/jcm12030928

Andersen KM, Joseph CS, Mehta HB, Streiff MB, Betz JF, Bollinger Jr RC, et al. Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 2022; 6(5): e12753.

Aljuhani O, Al Sulaiman K, Hafiz A, Eljaaly K, Alharbi A, Algarni R, et al. Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study. Saudi Pharmaceutical Journal. 2022; 30(4): 398-406. DOI:10.1016/j.jsps.2022.01.022

Al-Dorzi HM, Alqirnas MQ, Hegazy MM, Alghamdi AS, Alotaibi MT, Albogami MT, et al. Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. Journal of Critical Care Medicine. 2022; 8(4): 249-58. DOI:10.2478/jccm-2022-0023

AlLehaibi LH, Alomar M, Almulhim A, Al-Makki S, Alrwaili NR, Al-Bassam S, et al. Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence. Annals of Pharmacotherapy. 2023; 57(4): 361-74. DOI:10.1177/10600280221115299

Mennuni MG, Renda G, Grisafi L, Rognoni A, Colombo C, Lio V, et al. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. Journal of Thrombosis and Thrombolysis. 2021; 52(3): 782-90. DOI:10.1007/s11239-021-02401-x

Mattioli M, Benfaremo D, Mancini M, Mucci L, Mainquà P, Polenta A, et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. J Thromb Thrombolysis. 2021; 51(2): 286-92. DOI:10.1007/s11239-020-02243-z

Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Medical Research Methodology. 2021; 21: 1-9.

Quirk TJ, Quirk TJ. One-way analysis of variance (ANOVA). Excel 2007 for Educational and Psychological Statistics: A Guide to Solving Practical Problems. 2012: 163-79.

Kim H-Y. Statistical notes for clinical researchers: the independent samples t-test. Restorative Dentistry & Endodontics. 2019; 44(3).

Sheng Y. Testing the assumptions of analysis of variance. Best practices in quantitative methods. 2008: 324-40.

Ruxton GD, Beauchamp G. Time for some a priori thinking about post hoc testing. Behavioral ecology. 2008; 19(3): 690-3.

Kim TK, Park JH. More about the basic assumptions of t-test: normality and sample size. Korean journal of anesthesiology. 2019; 72(4): 331-5.

Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances. 2022; 6(17): 4915-23. DOI: 10.1182/bloodadvances.2022007561.